Palmar plantar erythrodysesthesia differential diagnosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 14: Line 14:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Additional diagnostic clues
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Additional diagnostic clues
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | Palmar plantar erythrodysesthesia
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | Palmar plantar erythrodysesthesia
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | The areas of well-defined intense erythema and edema
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | The areas of well-defined intense erythema and edema
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" |
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" |
* A variable degree of epidermal (keratinocytes) necrosis
* A variable degree of epidermal (keratinocytes) necrosis
* Vacuolar degeneration of the basal cell layer of epidermis
* Vacuolar degeneration of the basal cell layer of epidermis
Line 26: Line 26:
* Neutrophilic eccrine hidradenitis
* Neutrophilic eccrine hidradenitis
* Eccrine squamous syringometaplasia, in severe PPE (WHO grades 3 and 4)
* Eccrine squamous syringometaplasia, in severe PPE (WHO grades 3 and 4)
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | History of chemotherapeutic agent use
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | History of chemotherapeutic agent use
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x1
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x1
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x2
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x2
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x3
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x3
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x4
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x4
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x1
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x1
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x2
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x2
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x3
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x3
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x4
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x4
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x1
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x1
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x2
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x2
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x3
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x3
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x4
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x4
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x1
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x1
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x2
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x2
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x3
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x3
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x4
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x4
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x1
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x1
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x2
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x2
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x3
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x3
| style="background: #DCDCDC; padding: 5px; text-align: center;" valign="top" | x4
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x4
|-
|-
|}
|}

Revision as of 23:05, 30 July 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]

Overview

PPE must be differentiated from Graft-Versus-Host Disease (GVHD).

Differentiating palmar plantar erythrodysesthesia from other Diseases

Disease Clinical manifestation Histopathology Additional diagnostic clues
Palmar plantar erythrodysesthesia The areas of well-defined intense erythema and edema
  • A variable degree of epidermal (keratinocytes) necrosis
  • Vacuolar degeneration of the basal cell layer of epidermis
  • Spongiosis
  • Hyperkeratosis
  • Lymphohistiocytic infiltrates
  • Superficial perivascular infiltration of dermis by lymphocytes and eosinophils
  • Papillary dermal edema
  • Neutrophilic eccrine hidradenitis
  • Eccrine squamous syringometaplasia, in severe PPE (WHO grades 3 and 4)
 History of chemotherapeutic agent use
x1 x2 x3 x4
x1 x2 x3 x4
x1 x2 x3 x4
x1 x2 x3 x4
x1 x2 x3 x4

References

Retrieved from "https://www.wikidoc.org/index.php?title=Palmar_plantar_erythrodysesthesia_differential_diagnosis&oldid=1577518"